Most of these strategies target tumor-related genes/pathways that have proven to be relevant in liver cancer like the MET/HGF axis, the EGFR, ErbB-2A, Wnt, P53, PTEN, Akt, TGF-α, Myc, E2F, or KRAS pathways (Table 2) [149,150,237,238,239,240,241,242,243,244,245,246,247,248]. This evidence concerns the gene MYC and liver cancer.